253 related articles for article (PubMed ID: 37658893)
1. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles.
Nachit M; Dioguardi Burgio M; Abyzov A; Garteiser P; Paradis V; Vilgrain V; Leclercq I; Van Beers BE
Eur Radiol; 2024 Mar; 34(3):1461-1470. PubMed ID: 37658893
[TBL] [Abstract][Full Text] [Related]
2. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models.
Nachit M; De Rudder M; Thissen JP; Schakman O; Bouzin C; Horsmans Y; Vande Velde G; Leclercq IA
J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):144-158. PubMed ID: 33244884
[TBL] [Abstract][Full Text] [Related]
3. Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.
Lee SW; Huang DQ; Bettencourt R; Ajmera V; Tincopa M; Noureddin N; Amangurbanova M; Siddiqi H; Madamba E; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Yoneda M; Idilman R; Gumussoy M; Oz DK; Erden A; Loomba R
Aliment Pharmacol Ther; 2024 Jan; 59(1):80-88. PubMed ID: 37968251
[TBL] [Abstract][Full Text] [Related]
4. Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression.
Hsieh YC; Joo SK; Koo BK; Lin HC; Lee DH; Chang MS; Park JH; So YH; Kim W;
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):388-397.e10. PubMed ID: 35101634
[TBL] [Abstract][Full Text] [Related]
5. Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Li G; Rios RS; Wang XX; Yu Y; Zheng KI; Huang OY; Tang LJ; Ma HL; Jin Y; Targher G; Byrne CD; Pan XY; Zheng MH
Br J Nutr; 2022 Jun; 127(11):1613-1620. PubMed ID: 34176541
[TBL] [Abstract][Full Text] [Related]
6. Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
Nachit M; Kwanten WJ; Thissen JP; Op De Beeck B; Van Gaal L; Vonghia L; Verrijken A; Driessen A; Horsmans Y; Francque S; Leclercq IA
J Hepatol; 2021 Aug; 75(2):292-301. PubMed ID: 33865909
[TBL] [Abstract][Full Text] [Related]
7. MRI proton density fat fraction for estimation of tumor grade in steatotic hepatocellular carcinoma.
Kupczyk PA; Kurt D; Endler C; Luetkens JA; Kukuk GM; Fronhoffs F; Fischer HP; Attenberger UI; Pieper CC
Eur Radiol; 2023 Dec; 33(12):8974-8985. PubMed ID: 37368108
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.
Thompson SM; Garg I; Ehman EC; Sheedy SP; Bookwalter CA; Carter RE; Roberts LR; Venkatesh SK
Br J Radiol; 2018 Dec; 91(1092):20180345. PubMed ID: 30074820
[TBL] [Abstract][Full Text] [Related]
9. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
11. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
Bianco C; Jamialahmadi O; Pelusi S; Baselli G; Dongiovanni P; Zanoni I; Santoro L; Maier S; Liguori A; Meroni M; Borroni V; D'Ambrosio R; Spagnuolo R; Alisi A; Federico A; Bugianesi E; Petta S; Miele L; Vespasiani-Gentilucci U; Anstee QM; Stickel F; Hampe J; Fischer J; Berg T; Fracanzani AL; Soardo G; Reeves H; Prati D; Romeo S; Valenti L
J Hepatol; 2021 Apr; 74(4):775-782. PubMed ID: 33248170
[TBL] [Abstract][Full Text] [Related]
13. Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity.
Kim HK; Bae SJ; Lee MJ; Kim EH; Park H; Kim HS; Cho YK; Jung CH; Lee WJ; Choe J
Clin Mol Hepatol; 2023 Oct; 29(4):987-1001. PubMed ID: 37403320
[TBL] [Abstract][Full Text] [Related]
14. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.
Pal Chaudhary S; Reyes S; Chase ML; Govindan A; Zhao L; Luther J; Bhan I; Bethea E; Franses JW; Paige Walsh E; Anne Dageford L; Kimura S; Elias N; Yeh H; Markman J; Bozorgzadeh A; Tanabe K; Ferrone C; Zhu AX; Andersson K; Thiim M; Antonio Catalano O; Kambadakone A; Vagefi PA; Qadan M; Pratt D; Hashemi N; Corey KE; Misdraji J; Goyal L; Clark JW
Oncologist; 2023 Apr; 28(4):341-350. PubMed ID: 36763374
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
16. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
17. Myosteatosis in nonalcoholic fatty liver disease: An exploratory study.
De Munck TJI; Verhaegh P; Lodewick T; Bakers F; Jonkers D; Masclee AAM; Verbeek J; Koek GH
Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101500. PubMed ID: 32828745
[TBL] [Abstract][Full Text] [Related]
18. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
[TBL] [Abstract][Full Text] [Related]
19. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
[TBL] [Abstract][Full Text] [Related]
20. A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride.
Li S; Motiño O; Lambertucci F; Chen H; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Maiuri MC; Kroemer G; Martins I
Methods Mol Biol; 2024; 2769():57-65. PubMed ID: 38315388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
